Comparison tool

Ziconotide vs Pentadecapeptide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

ZiconotidePentadecapeptide

Share this peptide comparison

Property	Ziconotide	Pentadecapeptide
Category	Healing	Healing
Also known as	Prialt, SNX-111	BPC-157 Full Sequence, Stable Gastric Pentadecapeptide
FDA approved	Yes	No
Clinical status	FDA Approved - Severe chronic pain Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Chronic pain management, neuropathic pain	Tissue healing, gut health, injury recovery
How it works	Ziconotide is described as a synthetic form of omega-conotoxin MVIIA, a 25-amino-acid peptide originally associated with Conus magus venom. The source states that it inhibits N-type voltage-gated calcium channels in the spinal dorsal horn, which can reduce release of pain-related neurotransmitters. Limited blood-brain barrier penetration is given as the reason the evidence describes intrathecal rather than systemic administration.	Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.
Typical dosing	Limited community data available · See research protocols	Limited community data available · See research protocols
Research dosing	0.1-19.2 mcg/day intrathecal · Chronic use via intrathecal pump · Intrathecal infusion only	250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection
Typical duration	Chronic use via intrathecal pump	4-12 weeks typical
Administration	Intrathecal infusion only	Subcutaneous injection
Timing	Morning or as directed With or without food	Morning and evening; sometimes aligned with injury-related activity timing With or without food
Evidence level	FDA Approved	Preclinical
Possible side effects	Dizziness (Source reports dizziness and includes a 40% figure.) Nausea Confusion (Source includes confusion among notable neurologic adverse effects.) +6 more Hallucinations (Source links hallucinations to serious psychiatric risk.) Depression Suicidal ideation (Source includes suicidal thoughts among serious psychiatric concerns.) Memory impairment (Source reports memory problems as part of the adverse-effect profile.) Severe psychiatric symptoms (Source flags a black box warning and notes contraindication in people with a history of psychosis.) Intrathecal-only administration risk context (Source identifies Prialt as FDA approved and intrathecal only.)	Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.) Nausea (Reported side effect in the source.) Dizziness (Reported side effect in the source.) +1 more Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)
Research summary	The source characterizes ziconotide as an established drug rather than an early-stage research peptide, reporting FDA approval as Prialt in 2004 and European Commission approval in 2005. It describes use in severe chronic pain when intrathecal therapy is needed and other options are not tolerated or are inadequate. The source also notes a non-opioid profile with no reported tolerance or physical dependence signal in that summary, while emphasizing a narrow therapeutic window and important neuropsychiatric risks. Listed concerns include dizziness, confusion, memory impairment, gait instability, hallucinations, suicidal thoughts, and contraindication in people with a history of psychosis.	The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.
References	Peptibase peptides Peptibase peptides +2 more Peptibase peptides Peptibase peptides	Source Source +3 more Source Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Ziconotide

Pentadecapeptide

Category

Healing

Also known as

Prialt, SNX-111

BPC-157 Full Sequence, Stable Gastric Pentadecapeptide

FDA approved

Yes

Clinical status

FDA Approved - Severe chronic pain

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Preclinical; same research base as BPC-157. FDA Category 2 with pending reclassification context noted by the source.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Chronic pain management, neuropathic pain

Tissue healing, gut health, injury recovery

How it works

Ziconotide is described as a synthetic form of omega-conotoxin MVIIA, a 25-amino-acid peptide originally associated with Conus magus venom. The source states that it inhibits N-type voltage-gated calcium channels in the spinal dorsal horn, which can reduce release of pain-related neurotransmitters. Limited blood-brain barrier penetration is given as the reason the evidence describes intrathecal rather than systemic administration.

Pentadecapeptide is described as BPC-157, and its mechanism remains provisional. The supplied evidence emphasizes preclinical findings suggesting effects on angiogenesis, VEGFR2-associated pathways, nitric oxide signaling, and rodent dopaminergic, serotonergic, and adrenergic systems. The source also notes that no single clean receptor mechanism has been confirmed in humans.

Typical dosing

Limited community data available · See research protocols

Research dosing

0.1-19.2 mcg/day intrathecal · Chronic use via intrathecal pump · Intrathecal infusion only

250-500 mcg twice daily · Twice daily · 4-12 weeks typical · Subcutaneous injection

Typical duration

Chronic use via intrathecal pump

4-12 weeks typical

Administration

Intrathecal infusion only

Subcutaneous injection

Timing

Morning or as directed

With or without food

Morning and evening; sometimes aligned with injury-related activity timing

With or without food

Evidence level

FDA Approved

Preclinical

Possible side effects

Dizziness (Source reports dizziness and includes a 40% figure.)
Nausea
Confusion (Source includes confusion among notable neurologic adverse effects.)

+6 more

Hallucinations (Source links hallucinations to serious psychiatric risk.)
Depression
Suicidal ideation (Source includes suicidal thoughts among serious psychiatric concerns.)
Memory impairment (Source reports memory problems as part of the adverse-effect profile.)
Severe psychiatric symptoms (Source flags a black box warning and notes contraindication in people with a history of psychosis.)
Intrathecal-only administration risk context (Source identifies Prialt as FDA approved and intrathecal only.)

Generally well tolerated (Reported by the source, but not established through completed human clinical trials in the supplied evidence.)
Nausea (Reported side effect in the source.)
Dizziness (Reported side effect in the source.)

+1 more

Possible histamine release (The source advises caution for MCAS or histamine sensitivity.)

Research summary

The source characterizes ziconotide as an established drug rather than an early-stage research peptide, reporting FDA approval as Prialt in 2004 and European Commission approval in 2005. It describes use in severe chronic pain when intrathecal therapy is needed and other options are not tolerated or are inadequate. The source also notes a non-opioid profile with no reported tolerance or physical dependence signal in that summary, while emphasizing a narrow therapeutic window and important neuropsychiatric risks. Listed concerns include dizziness, confusion, memory impairment, gait instability, hallucinations, suicidal thoughts, and contraindication in people with a history of psychosis.

The supplied source describes a sizeable preclinical literature for BPC-157/Pentadecapeptide, including rodent and laboratory work on tendon, ligament, muscle, bone, and gastrointestinal models. It specifically notes a 2011 Journal of Applied Physiology tendon-cell study reporting increased outgrowth, survival, and migration. The same source cautions that recent reviews report no approved formulation, no validated human dose, and no completed Phase II trial, so human benefit claims remain extrapolations from non-human data. The source also notes WADA prohibition.

References

Peptibase peptides Peptibase peptides

+2 more

Peptibase peptides Peptibase peptides

Source Source

+3 more

Source Source Source

Full profile

View Details